Louisiana 2026 Regular Session Status: Enacted Bipartisan · 1 R · 1 D cosponsors

SB 401 — PHARMACEUTICALS: Provides for a Prescription Drug Affordability Board. (8/1/26)

Last action — Signed by the Governor. Becomes Act No. 915.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed Senate
  4. ✓
    Passed House
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced February 27, 2026. Enacted.

Signed by Governor Jeff Landry (Republican) on June 12, 2026.

Prognosis

Likely to advance 90% · high confidence

Where this bill stands today.

Odds of enactment

High

How often bills like it became law.

  • Enacted

    Current position in the legislative process.

  • 2 sponsors

    1 primary, 1 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (1 R · 1 D) — cross-party backing.

  • Cleared a recorded vote

    Passed 5 recorded votes so far.

Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.

In plain language

The bill establishes a Prescription Drug Affordability Board.

This legislation creates a board that will oversee and address the affordability of prescription drugs. It aims to ensure that drug prices are manageable for the public.

What this means for you
  • Consumers: This means you may see efforts to lower the costs of prescription drugs.

Bill Text

What changed in the latest version

333 added · 510 removed

Plain-language change summary

In the latest version of Bill SB 401, a reference to "ACT No. 915" has been removed. This change likely means that the specific act was either outdated or no longer relevant to the current legislation. By removing it, the bill can become clearer and more focused on current issues, which helps ensure that the laws are effective and up-to-date.

→
Previous
Latest
SLS 26RS-247 REENGROSSED Regular Session SENATE BILL NO.
Regular Session ENROLLED SENATE BILL NO.
401 BY SENATOR TALBOT PHARMACEUTICALS.
401 BY SENATOR TALBOT AND REPRESENTATIVE CHASSION AN ACT To amend and reenact R.S.
Provides for a Prescription Drug Affordability Board.
(8/1/26) AN ACT To amend and reenact R.S.
22:1870.10 through 1870.20, and to repeal R.S.
22:1870.10 through 1870.18, and to repeal R.S.
to require educational or marketing materials for prescription drugs directed to healthcare providers to include price information;
to require drug pricing transparency requirements;
to establish the minimum price information content;
to provide for annual report requirements;
to authorize enforcement pursuant to the Unfair Trade Practices and Consumer Protection Law;
to provide for reporting requirements of prescription drug price that increases over a certain amount;
to require reporting when a prescription drug's price increasesoveracertainamount;
to provide for manufacturers' obligations;
to provideforinformation requests bythe board;
to provide for webpage requirements;
to provideforpublicaccesstocertaindrugpricinginformation;toprovideforpenalties for violations;
to provide for public access to certain drug pricing information;
to provide for audits of reporting entities;
to provide for penalties for violations;
to provide for an annual report;
to provide for a public records exception;
to provide for public records exception;
Page 1 of 16 Coding:
Be it enacted by the Legislature of Louisiana:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 Be it enacted by the Legislature of Louisiana:
22:1870.10 through 1870.20, is herebyenacted to read as follows:
22:1870.10 through 1870.18, is herebyenacted to read as follows:
Therefore, the legislature hereby declares, in order to contain prescription drug costs, it is essential to understand the drivers of those costs, as transparency is typically the first step toward cost containment.
Therefore, the legislature hereby declares, in order to contain prescription drug costs, it is essential to understand the drivers of those costs, Page 1 of 11 Coding:
§1870.11.
Definitions As used in this Part, the following words have the following meanings unless the context indicates otherwise:
(1) "Average wholesale price" means the wholesale price charged on a specificprescriptiondrug that is assigned by the drug manufacturerand listed in a nationally recognized drug pricing file.
(2) "Board" means the Prescription Drug Affordability Board established pursuant to this Subpart.
(3) "Department" means the Department of Insurance.
(4) "Manufacturer" means any entity which is engaged in the production,preparation,propagation,compounding,conversion,orprocessing of prescription drugs for human use, whether directly or indirectly, by extraction from substances of natural origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, or any entity engaged in the packaging, repackaging, labeling, relabeling, or Page 2 of 16 Coding:
SLS 26RS-247 REENGROSSED SB NO.
SB NO.
401 distribution of prescription drugs.
401 ENROLLED as transparency is typically the first step toward cost containment.
§1870.11.
Definitions As used in this Part, the following words have the following meanings unless the context indicates otherwise:
(1) "Board" means the Prescription Drug Affordability Board established pursuant to this Subpart.
(2) "Department" means the Department of Insurance.
(3) "Enrollee" means any individual entitled to coverage of healthcare services.
(4) "Manufacturer" means any entity which is engaged in the production,preparation,propagation,compounding,conversion,orprocessing of prescription drugs for human use, whether directly or indirectly, by extraction from substances of natural origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, or any entity engaged in the packaging, repackaging, labeling, relabeling, or distribution of prescription drugs.
(6) "Prescription drug marketing" means to provide educational or marketing information or materialsin any formregardingaprescription drug including but not limited to all of the following:
(6) "Rebate" means either of the following:
(a) Face-to-face meetings.
(a) Drug manufacturer price concessions including but not limited to base price concessions, whether described as a rebate or otherwise, and any price protection rebates and performance-based price concessions that may accruedirectlyorindirectlytothepharmacybenefitmanager,healthinsurance issuer or health plan, or other party on behalf of the health insurance issuer or health plan, including a pharmacy benefit manager, from a manufacturer, dispensing pharmacy, or other party in connection with the dispensing or administration of a prescription drug.
(b) Physical mailings.
(b) Reasonable estimates of any other costs that are passed through or Page 2 of 11 Coding:
(c) Telephone conversations.
Words which are struck through are deletions from existing law;
(d) Electronic mail or facsimile.
words in boldface type and underscored are additions.
Show all 312 changed rows (272 more)
Previous
Latest
SB NO.
401 ENROLLED are reasonably anticipated to be passed through to the health insurance issuer or health plan and serve to reduce the health insurance issuer or health plan's liabilities for a prescription drug.
(8) "Wholesale acquisition cost" or "WAC" has the same meaning as provided in at 42 U.S.C.
(8) "Wholesale acquisition cost" or "WAC" has the same meaning as provided in 42 U.S.C.
(6) Two public members appointed by the speaker of the House of Page 3 of 16 Coding:
(6) Two public members appointed by the speaker of the House of Representatives.
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 Representatives.
C.
C.The public members shall have a significant healthcareorpharmacy background.
The public membersshall haveasignificanthealthcare or pharmacy background.
(2) Each public member shall hold office for the term of appointment and until their successor is appointed and qualified.
(2) Each public member shall hold office for the term of appointment and until his successor is appointed and qualified.
Any vacancy in the membership of the board shall be filled for the unexpiredterminthemannerprovidedfortheoriginalappointment.Members shall be eligible for reappointment to the board.
Any vacancy in the membership of the board shall be filled for the unexpiredterminthemannerprovidedfortheoriginalappointment.Members Page 3 of 11 Coding:
F.(1)Theboardshallorganizeassoonaspossible aftertheappointment ofitsmembersandshallannuallyelectachairpersonandvicechairpersonfrom among its members, and a secretary who need not be a member of the board.
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SB NO.
401 ENROLLED shall be eligible for reappointment to the board.
F.(1)Theboard shallorganizeassoonaspossibleaftertheappointment ofitsmembersandshallannuallyelectachairpersonandvicechairpersonfrom among its members, and a secretary who need not be a member of the board.
Page 4 of 16 Coding:
K.
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 K.
Generic or biosimilar drugs shall be placed on thelist only if theyhaveawholesale acquisition costof one hundred dollars or more for a unit costincreaseof morethan twohundred percent during any twelve-month period.
Generic or biosimilar drugs shall be placed on thelist only if theyhaveawholesale acquisition costof one hundred dollars ormoreforaunit costincreaseof morethan two hundred percent during any twelve-month period.
In developing the list required by Subsection A of this Section, the board shall consider, at a minimum, all of the following factors:
In developing the list required by Subsection A of this Section, the Page 4 of 11 Coding:
(1)Thecostofthedrugtopublic healthcareprogramsincluding butnot limited to Medicaid.
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SB NO.
401 ENROLLED board shall consider, at a minimum, all of the following factors:
(1)Thecostofthedrugtopublic healthcareprogramsincludingbutnot limited to Medicaid.
The list developed pursuant to this Section shall be reviewed and Page 5 of 16 Coding:
The list developed pursuant to this Section shall be reviewed and updated by the board at least once every three years.
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 updated by the board at least once every three years.
For each prescription drug that the board places on the critical prescription drug list pursuant to R.S.
By June first of each calendar year, the board shall identifyup to ten prescriptiondrugsonwhichthestatespendssignificanthealthcaredollars,after accounting for rebates.
22:1870.13, the board shall require the manufacturer of the drug to report the following information to the board:
The drugs identified shall represent different drug classes and may include generics.
(1) Total cost of production and approximate cost of production per dose.
B.ForeachprescriptiondrugidentifiedpursuanttoSubsectionAofthis Section, the board shall require the drug's manufacturer to report all of the following:
(2)Researchanddevelopmentcostsofthedrugincludingbutnotlimited to all of the following:
(1) The drug's wholesale acquisition cost increase.
(a) Research and development costs that are paid with public funds.
(2) The manufacturer's aggregate company-level research and development and other relevant capital expenditures for the most recent year Page 5 of 11 Coding:
(b)After-taxresearchanddevelopmentcostspaidbythemanufacturer.
(c) Research and development costs paid by third parties.
(3) Marketing and advertising costs for the drug, apportioned by marketing activities that are directed to consumers, marketing activities that are directed to prescribers, and the total cost of all marketing and advertising that is directed primarily to Louisiana consumers and prescribers.
(4) The prices for the drug that are charged to purchasers outside the United States, by country, for a representative set of countries determined by the board.
(5)(a) Prices charged to typical Louisiana purchasers including but not limited to all of the following:
(i) Local pharmacies, as defined in R.S.
22:1863.
(ii) Pharmacy chains.
(iii) Pharmacy wholesalers.
(iv) Other direct purchasers.
(b) True net-typical prices charged to prescription drug benefit managers for distribution in Louisiana, net of any rebates or other payments from the manufacturer to the pharmacy benefit manager and the pharmacy benefit manager to the manufacturer.
Page 6 of 16 Coding:
SLS 26RS-247 REENGROSSED SB NO.
SB NO.
401 B.
401 ENROLLED for which final audited data is available.
To the extent a manufacturer cannot fulfill its obligation to reportas required in Subsection A of this Section without disclosing proprietary, trade secret, or similarly sensitive information to an individual employed by or representing an entity whose interest in the information conflicts with that of the manufacturer, the manufacturer may instead report information to the commissioner.
(3) A written description, suitable for public release, of factors that contributed to any reported increase in wholesale acquisition cost for the reporting year.
The commissioner shall review the submitted information to determine whether it should be disclosed to the board without redaction.
C.
In reviewing the information, the commissioner shall draw upon all reasonable inferencesinfavorofsustainingthemanufacturer'sassertionofconfidentiality.
The quality and types of information and data that a drug manufacturer submits to the board under this Section shall be consistent with the quality and types of information and data that the manufacturer includes in the manufacturer's annual consolidated report on Securities and Exchange Commission Form 10-K or any other public disclosure.
Upon reachinga determination, the commissioner shall submittotheboard all submitted information deemed not covered by this Subsection and a summary ofanyinformationthatmaybesummarizedwithoutdisclosingtheinformation determinedtobeproprietary,tradesecret,orsimilarlysensitive,andshallhold all other information strictly confidential.
D.
Any information submitted to the commissionerandheldconfidentialpursuanttothisSubsectionshallbeexempt from disclosure under the laws of this state.
By December thirty-first of each calendar year, the board shall publish a report on its website based on the information that it receives pursuant to Subsection B of this Section.
E.
Information provided to the board pursuant to Subsection B of this Section is exempt from public inspection and copying pursuant to the Public Records Law, R.
S.
44:1 et seq.
Confidentiality A.
Confidentiality A.Allinformationanddataobtainedbythedepartmentpursuanttothis Subpart that are not otherwise publicly available are considered to be a trade secret, confidential, and proprietary information.
Information reported to the board pursuant to R.S.
Such information and data are not subject to disclosure pursuant to the Public Records Law, R.S.
22:1870.14 shall not be deemed to be a public or government record.
44:1 et seq.
The information shall be kept confidential and shall be exempt from disclosure.
B.(1) Information provided to the department, board, or an interested Page 6 of 11 Coding:
B.
Any public reporting of information submitted pursuant to R.S.
Page 7 of 16 Coding:
SLS 26RS-247 REENGROSSED SB NO.
SB NO.
401 22:1870.14 shall be aggregated to protect the financial, competitive, or proprietary nature of the information.
401 ENROLLED party pursuant to this Subpart shall, except to the extent it is already in the public domain, be considered trade secret pursuant to the Uniform Trade SecretsAct,R.S.51:1431etseq.,exemptfromdisclosurepursuanttothePublic RecordsLaw,R.S.44:1etseq.,andshallnotbediscloseddirectlyorindirectly.
(2)Excepttoprovidethegeneralpublic withwholesaleacquisitioncosts under R.S.
22:1870.18(A)(2) of this Subpart, the department, board, or interested parties and their agents shall not publish or otherwise disclose any information that would allow for the identification of an individual drug, therapeuticclassofdrugs,ormanufacturer;thatwouldrevealthepricesofany drug or therapeutic class of drugs;
or that has the potential to compromise the financial, competitive, or proprietary nature of any information submitted by the manufacturer pursuant to this Subpart.
(3)Thedepartment,board,andinterestedthirdpartiesshallimposethe confidentiality protections of this Subpart on any third party that may receive or otherwise have access to this information.
(2) The board shall identify and include in the report a list of those prescription drugs that have a cost in Louisiana that is excessively high when compared with the cost of the drug in other states and countries and when compared with the overall cost of researching, developing, and producing the drug in light of the number of years the drug has been made available for distribution.
(2) The board shall identify and include in the report a list of those prescription drugs that have a cost in this state that is excessively high when compared with the cost of the drug in other states and countries and when compared with the overall cost of researching, developing, and producing the drug in light of the number of years the drug has been made available for distribution.
B.TheboardshallsubmitthereporttotheHouseandSenatecommittees on insurance no later than sixtydays priortothe start of the regular legislative session.
B.TheboardshallsubmitthereporttotheHouseandSenatecommittees Page 7 of 11 Coding:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SB NO.
401 ENROLLED on insurance no later than sixty days prior tothestartof the regular legislative session.
Disclosure of prescription drug price information;
Prescription drug pricing transparency;
educational or marketing materials;
annual report;
minimum content;
webpage requirements and publications;
violations A.
penalty and enforcement A.(1) Not later than January fifteenth of each calendar year, a pharmaceutical drug manufacturer shall submit a report to the department statingthecurrentwholesale acquisition costinformation fortheUnitedStates FoodandDrugAdministration-approvedprescriptiondrugssoldinorintothis state by that manufacturer.
Any person engaging in any form of prescription drug marketing directlytoahealthcareproviderwiththeintentthattheprovidermayprescribe thedrugforusebyhispatientsshallincludepriceinformationinthematerials.
(2) The department shall develop a webpage that provides the general public with prescription drug price information submitted pursuant to this Section.Thewebpageshallbemadeavailableonthedepartment'swebsitewith a dedicated link that is prominently displayed on the home page or by a separate easily identifiable webpage address.
B.
B.(1) This Section applies only to prescription drugs with a wholesale acquisition cost of at least one hundred dollars for a thirty-day supply before the effective date of an increase described by this Section.
The price information required by Subsection A of this Section shall include, at a minimum, all of the following:
(2) Not later than the thirtieth day after the effectivedate of an increase of forty percent or more over the preceding three calendar years or fifteen percentormoreintheprecedingcalendaryearinthewholesaleacquisitioncost of a prescription drug to which this Section applies, a pharmaceutical drug manufacturer shall submit a report to the commissioner.
(1)Thedatethattheeducationalormarketingmaterialswereprepared.
The report shall include all of the following information:
(2) The name of the drug and of the current manufacturer.
(a) The name of the prescription drug.
Page 8 of 16 Coding:
(b) Whether the prescription drug is a brand name or generic.
(c) The effective date of the change in wholesale acquisition cost.
(d) A statement regarding the factor or factors that caused the increase in the wholesale acquisition cost and an explanation of the role of each factor's impact on the cost.
Page 8 of 11 Coding:
SLS 26RS-247 REENGROSSED SB NO.
SB NO.
401 (3)(a) The average wholesale price of a thirty-day supply of the drug describedinthematerialsasofthedatetheeducationalormarketingmaterials were prepared.
401 ENROLLED (3) If, during a calendar year, a prescription drug with a wholesale acquisitioncostofatleastonehundreddollarsforathirty-daysupplyincreases in price by forty percent or more over the preceding three calendar years or fifteen percent or more in the preceding calendar year in the wholesale acquisition cost of the prescription drug, the pharmaceutical drug manufacturer shall include in the annual report submitted pursuant to this Section all of the following information:
(b) If the described drug is designed to be administered for a duration oftherapyoflessthanthirtydays,theproposeddurationandaveragewholesale price for that period of time as of the date the educational or marketing materials were prepared.
(a) Aggregate, company-level research and development costs for the most recent year for which final audit data is available.
(c) The disclosure of the average wholesale price shall account for each labeled indication and reflect any differences as a result of different strengths and dosage forms approved for sale.
(b)Thenameofeachofthemanufacturer'sprescriptiondrugsapproved by the United States Food and Drug Administration in the previous three calendar years.
(4) The date that the drug was first marketed in the United States and the average wholesale price as of that date.
(c) The name of each of the manufacturer's prescription drugs that lost patent exclusivity in the United States in the previous three calendar years.
(5) The average wholesale price on each date that the price of the drug has changed since the drug was first marketed in the United States.
(4) A manufacturer's obligations pursuant to this Subsection shall be fully satisfied by the submission of information and data that a manufacturer includes in the manufacturer's annual consolidated report on Securities and Exchange Commission Form 10-K or any other public disclosure.
C.(1) The disclosures required by this Section shall be made on a form and in a manner prescribed by the commissioner.
(2) The completed form shall be provided to the healthcare provider at the same time and in the same manner as any other marketing materials provided to the provider.
If the marketing activities are performed telephonically,thentheformshallbesenttothehealthcareproviderbymailor electronically within one business day of the marketing activity.
D.
A violation of any provision of this Section shall constitute a prohibitedpracticeundertheUnfairTradePracticesandConsumerProtection Law, R.S.
51:1401 et seq., and shall besubjectto the enforcement provisions of that Chapter.
E.
The commissioner shall adopt, pursuant to the Administrative Procedure Act, R.S.
49:950 et seq., any rules and regulations necessary to implement and enforce the provisions of this Section.
§1870.19.
Prescription drug pricing transparency Page 9 of 16 Coding:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 A.(1) A pharmaceutical drug manufacturer shall notify the board no later than thirty days after any of the following occur:
(a) The wholesale acquisition drug cost of a brand name drug increases bymorethanthepercentagechangefromtheprecedingyearintheprescription drug component of theConsumerPriceIndex of theUnited States Department of Labor, Bureau of Labor Statisticsperpricing unit during any twelve-month period.
(b) The wholesale acquisition drug cost of a generic or biosimilar drug with a wholesale acquisition cost of one hundred dollarsormoreforaunit cost increase of more than two hundred percent during any twelve-month period.
(c) A new drug is introduced for distribution in the state that has a wholesale acquisition cost greater than the amount that causes the drug to be considered a specialty drug under the Medicare Part D program.
(2)ForanyprescriptiondrugreportedpursuanttoParagraph(1)ofthis Subsection, the manufacturer shall report to the board the following information about the drug:
(a) An explanation of the increase, including whether it was in response toanyrebate,otherincentiveorinducement,includingdiscounts,orformulary requirement.
(b)The totalcost of production and approximatecostof production per pricing unit.
(c)Researchanddevelopmentcostsofthedrugincludingbutnotlimited to all of the following:
(i) Research and development costs that are paid with public funds.
(ii)After-taxresearchanddevelopmentcostspaidbythemanufacturer.
(iii) Research and development costs paid by third parties.
(iv) Marketing and advertising costs for the drug, apportioned by marketing activities that are directed to consumers, marketing activities that are directed to prescribers, and the total cost of all marketing and advertising Page 10 of 16 Coding:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 that is directed primarily to Louisiana consumers and prescribers.
B.
No later than thirty days after receipt of a notice provided for in SubsectionAofthisSection,theboardshallrequestpricingcomponentdataper pricing unit for the prescription drug from each reporting entity.
No later than sixty days fromthedateof receivingarequestfromthe board, a reporting entity shall notify the board of pricing component data per pricing unit of the prescription drug.
Not later than the sixtieth day after receipt of the report submitted, the department shall publish the cost increase information required pursuant to this Section on the department's webpage for prescription drug price information.
D.
D.(1) If the department determines that a pharmaceutical drug manufacturer failed to submit a report, or failed to submit the report in the manner prescribed by Subsection B of this Section and the rules adopted pursuant to this Section, the department shall provide written notice of the failure to the manufacturer.
Each reporting entity that submits a notification or report pursuant to this Section shall submit with the notification or report a signed written certification of the notification's or report's accuracy.
(2) On receipt of notice described by this Subsection, a pharmaceutical drug manufacturer shall submit a report that does all of the following:
E.
(a) Complies with Subsection B of this Section and rules adopted Page 9 of 11 Coding:
The information provided for in Subsections A and C of this Section shall be made publicly accessible on the website of both the Department of Insurance and the Louisiana Department of Health.
F.Thefailureofanyreportingentitytoprovideinformationrequiredby this Section shall be considered an unfair method of competition and unfair practice or act in accordance with the Unfair Trade Practices and Consumer Protection Law, R.S.
51:1401 et seq.
In addition to any enforcement actions taken by the commissioner as authorized pursuant to this Title, the commissioner on behalf of the board shall refer any reporting entity that fails to provide a notification or report required by this Section to the attorney general.
G.
The Department of Insurance and the Louisiana Department of Health may audit the data submitted by a reporting entity pursuant to this Subpart.
The reporting entity shall pay for the costs of the audit.
H.
By January first of each year, the board shall produce an annual report and submit the report to the governor, the president of the Senate, and the speaker of the House of Representatives.
The report shall include all of the following:
(1)Informationdevelopedfromthedisclosuresreceivedpursuanttothis Page 11 of 16 Coding:
SLS 26RS-247 REENGROSSED SB NO.
SB NO.
401 Subpart on trends in the cost of prescription drugs, analysis of manufacturer prices and price increases, the major components of prescription drug pricing along the supply chain and the impacts on insurance premiums and cost sharing, and any other information the board determines is relevant to providing greaterconsumerawarenessofthefactorscontributingtothecostof prescription drugs in the state.
401 ENROLLED pursuant to this Section.
(2)Informationidentifyingthetwenty-fivecostliestdrugsinthestate,the twenty-five most frequently prescribed drugs in the state, and the twenty-five drugs with the highest year-over-year cost increases.
(b) Addresses all issues raised in the notice.
I.
(3) The department may not assess an administrative penalty pursuant tothisSubsectionagainstapharmaceuticaldrugmanufacturerthatsubmitsto the department the required report, as applicable, on or before the forty-fifth day after the date the manufacturer receives notice pursuant to this Section.
For purposes of this Section, the following definitions shall apply:
E.(1) The department may assess an administrative penalty against a manufacturer that violates this Section or rules pursuant to this Subsection.
(1) "Affiliated manufacturer" means a drug or biological product manufacturer that, either directly or indirectly through one or more intermediaries:
(2) In determining the amount of the penalty, the department shall consider all of the following:
(a) Has an investment or ownership interest in a pharmacy benefit manager licensed by the commissioner.
(a) The manufacturer's previous violations.
(b) Shares common ownership with a pharmacy benefit manager licensed by the commissioner.
(b) The seriousness of the violation.
(c) Has an investor or a holder of an ownership interest in a pharmacy benefit manager licensed by the commissioner.
(c) The manufacturer's demonstrated good faith.
(2)"Prescriptiondrug"or"drug"meansadrugthatisrequiredbyany applicable federal or state law or regulation to be dispensed or delivered pursuant only to a prescription drug order, or is restricted to use by practitioners only and includes biological products.
(d) Any other matters as justice may require.
The term is limited to prescription drugs and biological products intended for human use.
(3) The penalty may not exceed one thousand dollars a day for each violation.
(3) "Reporting entity" means a manufacturer, affiliated manufacturer, grouppurchasing organization,rebateaggregator,wholesaledrugdistributor, pharmacy benefits manager, and any other entity in the supply chain between the manufacturer and pharmacy.
(4) Each day a violation continues may be considered a separate violation.
§1870.20.
(5) The enforcement of the penalty may be stayed during the time the order is under judicial review if themanufacturerpays the penalty to the clerk of the court or files a securitybond with thecourt in the amount of the penalty.
Termination Page 12 of 16 Coding:
(6) The attorney general may sue tocollectthepenalty.Money collected pursuant to this Section shall be deposited in the state treasury and may be appropriated only to the department for the purposes of administering this Section.
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 The provisions of this Subpart shall terminate on June 30, 2028.
Exceptions * * * B.Thelegislaturefurtherrecognizesthatthereexistexceptions,exemptions, and limitations to the laws pertaining to public records throughout the revised statutesandcodesofthisstate.Therefore,thefollowingexceptions,exemptions,and limitations are hereby continued in effect by incorporation into this Chapter by citation:
Exceptions * * * B.Thelegislaturefurtherrecognizesthatthereexistexceptions,exemptions, and limitations to the laws pertaining to public records throughout the revised Page 10 of 11 Coding:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SB NO.
401 ENROLLED statutesandcodesofthisstate.Therefore,thefollowingexceptions,exemptions,and limitations are hereby continued in effect by incorporation into this Chapter by citation:
Section4.ThisActshalltakeeffectandbecomeoperativeifandwhentheActwhich originated as Senate Bill No.
Section 4.
387 of this 2026 Regular Session of the Legislature is enacted and becomes effective.
The provisions of Sections 1, 2, and 3 of this Act shall take effect and become enforceable on January 1, 2027, only if Section 7 of the Act which originated as Senate Bill No.
If vetoed by the governor and subsequently approved by the legislature, this Act shall become effective on the date that Senate Bill No.
387 of the 2026 Regular Session of the Legislature is enacted and becomes effective.
387 becomes effective.
PRESIDENT OF THE SENATE SPEAKER OF THE HOUSE OF REPRESENTATIVES GOVERNOR OF THE STATE OF LOUISIANA APPROVED:
The original instrument and the following digest, which constitutes no part of the legislative instrument, were prepared by Senate Legislative Services.
Page 11 of 11 Coding:
The keyword, summary, and digest do not constitute part of the law or proof or indicia of legislative intent.
[R.S.
1:13(B) and 24:177(E)] DIGEST SB 401 Reengrossed 2026 Regular Session Talbot Proposed law defines "average wholesale price", "board", "department", "manufacturer", "prescription drug", "prescription drug marketing", "research and development expenditures", and "wholesale acquisition cost".
Page 13 of 16 Coding:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 ProposedlawestablishesthePrescriptionDrugAffordabilityBoard(board)withintheDept.
of Insurance, consisting of the following members:
(1) The commissioner of insurance, or his designee.
(2) The secretaryof the La.
Dept.
of Health, or his designee.
(3) The president of the La.
Board of Pharmacy, or his designee.
(4) Two public members appointed by the governor.
(5) Two public members appointed by the president of the Senate.
(6) Two public members appointed by the speaker of the House of Representatives.
(7) One member representinga patient advocacygroup appointed bythe commissioner of insurance.
Proposed law requires the public members to have a significant health care or pharmacy background and provides that each shall serve for a term of five years.
Proposed law prohibits conflicts of interest byboard members.
Further provides that actual or potential conflicts of interest be disclosed prior to appointment to the board.
Proposed law requires the board to develop a list of critical prescription drugs made available in La., for which there is a substantial public interest in understanding the developmentofpricingforthedrugs.
Providesthatgenericorbiosimilar drugs beplacedon the list in certain circumstances.
Proposed law requires the manufacturer of each prescription drug that the board places on the critical prescription drug list to report the following information to the board:
(1) Total cost of production and approximate cost of production per dose.
(2) Research and development costs of the drug.
(3) Marketing and advertising costs for the drug, apportioned by marketing activities that are directed to consumers, marketing activities that are directed to prescribers, and the total cost of all marketing and advertising that is directed primarily to La.
consumers and prescribers.
(4) The prices for the drug that are charged to purchasers outside the U.S., by country, for a representative set of countries determined bythe committee.
(5) Prices charged to typical La.
purchasers.
Proposed law establishes a price increase threshold for reporting by generic and biosimilar manufacturers.
Proposed law provides that failure of a manufacturer to provide the required information is a prohibited practice under the Unfair Trade Practices and Consumer Protection Law.
Proposed law provides for disclosure of proprietary or confidential information to the commissioner of insurance.
Further provides that proprietaryor confidential information is exempt from public records laws.
Proposedlawrequiresinformationreportedtotheboardtobekeptconfidentialandprohibits thedisclosureoftheinformationas a public record.Further requiresanypublicreportingof Page 14 of 16 Coding:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 information to be aggregated to protect the financial, competitive, or proprietary nature of the information.
Proposed law requires the board to preparean annual report on prescription drugprices and theirroleinoverallhealthcarespendinginthestatebasedonthedatasubmittedtotheboard.
Furtherrequiresthe board to include in the report a list of thoseprescriptiondrugs thathave a cost in La.
that is excessivelyhigh when comparedwith the cost of the drugin otherstates and countries and when compared with the overall cost of researching, developing, and producing the drug in light of the number of years the drug has been made available for distribution.
Proposed law requires any person engaging in any form of prescription drug marketing directlyto a healthcare provider with the intent that the provider mayprescribe the drug for use by his patients to include, at a minimum, the following price information in the materials:
(1) The date that the educational or marketing materials were prepared.
(2) The name of the drug and of the current manufacturer.
(3) The average wholesale price of a 30-day supply of the drug described in the materials, or if the described drug is designed to be administered for a duration of therapyof less than 30 days, the proposed duration and average wholesale price for that period of time.
(4) ThedatethatthedrugwasfirstmarketedintheU.S.
andtheaveragewholesaleprice as of that date.
(5) The average wholesale price on each date that the price of the drug has changed since the drug was first marketed in the U.S.
Proposed law requires the completed form to be provided to the healthcare provider at the sametimeandinthesamemannerasanyothermarketingmaterialsprovidedtotheprovider.
Furtherprovides,ifthemarketingactivitiesareperformedtelephonically,theformtobesent tothehealthcareproviderbymailorelectronicallywithinonebusinessdayofthemarketing activity.
A violation of proposed law constitutes a prohibited practice under the Unfair Trade Practices and Consumer Protection Law.
Effective August 1, 2026.
(Amends R.S.
44:4.1(B)(11);
adds R.S.
22:1870.10-1870.20;
repeals R.S.
22:1870(B)(5)) Summary of Amendments Adopted by Senate CommitteeAmendmentsProposedbySenateCommitteeonInsurancetotheoriginal bill 1.
Requires notification when the wholesale acquisition cost of a name brand drug increases by more than the CPI during any 12-month period.
2.
Requires notification when the wholesale acquisition cost of a generic drug increases by more than $100, or by $200 total, in any 12-month period.
3.
Requires an explanation for the increase in price, including specified information about factors that make up the price.
Page 15 of 16 Coding:
Words which are struck through are deletions from existing law;
words in boldface type and underscored are additions.
SLS 26RS-247 REENGROSSED SB NO.
401 4.
Requires the reported information be made publiclyavailable.
5.
Requires an annual report.
6.
Sunsets the board on June 30, 2028.
7.
Repeals present law requiringnotice of amorethan15%increasein the cost of a brand name drug.
8.
Makes proposed law effective when SB 387 is enacted.
9.
Makes technical changes.
Senate Floor Amendments to engrossed bill 1.
Changespriceincreasereportingthresholdsforgenericandbiosimilardrugs.
2.
Allows manufacturers to submit proprietary or sensitive information to the commissioner of insurance to review.
3.
Exempts from public disclosure proprietary or sensitive information submitted to the commissioner.
4.
Adds definitions for research and development expenditures and wholesale acquisition cost.
5.
Adds a member to the board.
6.
Prohibitsmembersoftheboardfromhavingconflictsofinterestandrequires disclosure of potential or actual conflicts of interest prior to appointment to the board.
7.
Makes technical changes.
Page 16 of 16 Coding:
⬇ Download PDF
View plain text versions (6)

Amendments

17 amendments

Click Show changes on an amendment above to see how it modifies the bill.

Action History

  1. Signed by the Governor. Becomes Act No. 915.

  2. Effective date: See Act.

  3. Enrolled. Signed by the President of the Senate.

  4. Signed by the Speaker of the House.

  5. Sent to the Governor by the Secretary of the Senate on 6/2/2026.

  6. Conference Committee Report read, roll called, yeas 89, nays 6. The Conference Committee Report was adopted.

  7. Notice House adopted the Conference Committee Report.

  8. Conference Committee report received. Lies over under the rules.

  9. Rules suspended.

  10. Conference Committee Report read; adopted by a vote of 36 yeas and 0 nays.

  11. Notice of Senate adoption of Conference Committee Report.

  12. Scheduled for floor debate on 05/31/2026.

  13. Notice House Conference Committee members appointed.

  14. Notice of Senate rejecting House amendments.

  15. Senate conference committee members appointed: Talbot, Bass, and Myers.

  16. House conferees appointed: Chance Henry, Firment, and Miller.

  17. Notice of Senate conferees appointed.

  18. Amendments proposed by the House read and rejected by a vote of 36 yeas and 0 nays.

  19. Read third time by title, amended, roll called on final passage, yeas 96, nays 0. Finally passed, ordered to the Senate.

  20. Received from the House with amendments.

  21. Read by title, amended, passed to 3rd reading.

  22. Scheduled for floor debate on 05/19/2026.

  23. Reported without Legislative Bureau amendments.

  24. Reported with amendments (13-0). Referred to the Legislative Bureau.

  25. Read by title, amended, recommitted to the Committee on House and Governmental Affairs.

  26. Reported with amendments (11-0). To be recommitted to the Committee on House and Governmental Affairs.

  27. Read by title, under the rules, referred to the Committee on Insurance.

  28. Received in the House from the Senate, read by title, lies over under the rules.

  29. Called from the Calendar.

  30. Senate floor amendments read and adopted. Read by title and passed by a vote of 37 yeas and 0 nays; ordered reengrossed and sent to the House. Motion to reconsider tabled.

  31. Read by title and returned to the Calendar, subject to call.

  32. Read by title. Committee amendments read and adopted. Ordered engrossed and passed to third reading and final passage.

  33. Reported with amendments.

  34. Introduced in the Senate; read by title. Rules suspended. Read second time and referred to the Committee on Insurance.

  35. Prefiled and under the rules provisionally referred to the Committee on Insurance.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 1 co-sponsors · 145 not signed on · 6 voted No

Sponsors (1)

Co-sponsors (1)

Not signed on (145)

145 members have not signed on to this bill.

Show all 145 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

ADOPT CONFERENCE REPORT (#1801)

Passed 89 Yea · 6 Nay · 10 Other
Party YeaNayPresentNot Voting
Democrat 20604
Republican 64004
Unaffiliated 5002
Total 896010
% of votes cast 85%6%0%10%
How each member voted (105)
Member Party Vote
Amedee — Yea
Stagni — Yea
Mr. Speaker — Not Voting
Galle — Not Voting
Johnson, T. — Yea
Landry, T. — Yea
St. Blanc — Yea
Adrian Fisher Democrat Nay
Aimee Adatto Freeman Democrat Yea
Alonzo L. Knox Democrat Yea
Barbara Carpenter Democrat Yea
C. Denise Marcelle Democrat Nay
Candace N. Newell Democrat Nay
Chasity Martinez Democrat Yea
Dana Henry Democrat Yea
Delisha Boyd Democrat Yea
Ed Murray Democrat Yea
Edmond Jordan Democrat Not Voting
Gerald Boudreaux Democrat Yea
III, Ed Larvadain Democrat Nay
Joy Walters Democrat Not Voting
Jr., Kyle M. Green Democrat Yea
Ken Brass Democrat Yea
Mandie Landry Democrat Yea
Marcus Anthony Bryant Democrat Yea
Pat Moore Democrat Yea
Rashid Armand Young Democrat Nay
Robby Carter Democrat Yea
Rodney Lyons Democrat Yea
Roy Daryl Adams Democrat Yea
Shaun Raphael Mena Democrat Nay
Sr., Wilford Carter Democrat Not Voting
Steven Jackson Democrat Yea
Sylvia Elaine Taylor Democrat Yea
Tammy T. Phelps Democrat Not Voting
Tehmi Jahi Chassion Democrat Yea
Vanessa Caston LaFleur Democrat Yea
Annie Spell Republican Yea
Barbara Reich Freiberg Republican Yea
Beth Anne Billings Republican Yea
Brett F. Geymann Republican Not Voting
Brian Leonard Glorioso Republican Yea
Bryan Fontenot Republican Yea
Chad Michael Boyer Republican Yea
Chance Keith Henry Republican Yea
Christopher Turner Republican Yea
Danny McCormick Republican Yea
Daryl Andrew Deshotel Republican Yea
Debbie Villio Republican Yea
Dixon Wallace McMakin Republican Yea
Dodie Horton Republican Yea
Emily Chenevert Republican Yea
Foy Bryan Gadberry Republican Yea
Francis C. Thompson Republican Yea
Gregory A. Miller Republican Yea
III, Roger William Wilder Republican Yea
III, Vincent E. Cox Republican Yea
IV, Gerald "Beau" Beaullieu Republican Yea
Jack McFarland Republican Yea
Jacob Braud Republican Yea
Jacob Jules Landry Republican Yea
Jason Brian DeWitt Republican Yea
Jeffrey "Jeff" Fons Wiley Republican Yea
Jeremy LaCombe Republican Not Voting
Jerome Zeringue Republican Yea
Jessica Domangue Republican Yea
John E. Wyble Republican Yea
Joseph A. Orgeron Republican Yea
Josh Carlson Republican Yea
Jr., Dennis Bamburg Republican Yea
Jr., John R. Illg Republican Yea
Jr., Michael Robert Bayham Republican Not Voting
Kathy Edmonston Republican Yea
Kellee Hennessy Dickerson Republican Yea
Kim Carver Republican Yea
Kimberly Landry Coates Republican Yea
Larry A. Bagley Republican Not Voting
Lauren Ventrella Republican Yea
Laurie Schlegel Republican Yea
Les Farnum Republican Yea
Mark Wright Republican Yea
Michael "Gabe" Firment Republican Yea
Michael Charles Echols Republican Yea
Michael Melerine Republican Yea
Mike Johnson Republican Yea
Neil Riser Republican Yea
Nicholas Muscarello Republican Yea
Paul Sawyer Republican Yea
Phillip Eric Tarver Republican Yea
Polly Thomas Republican Yea
R. Dewith Carrier Republican Yea
Raymond J. Crews Republican Yea
Reese "Skip" Broussard Republican Yea
Rhonda Gaye Butler Republican Yea
Robert "Bob" Owen Republican Yea
Rodney Schamerhorn Republican Yea
Ryan Bourriaque Republican Yea
Shane Mack Republican Yea
Sr., Peter F. Egan Republican Yea
Stephanie H. Berault Republican Yea
Stephanie Hilferty Republican Yea
Timothy P. Kerner Republican Yea
Tony Bacala Republican Yea
Troy Jude Hebert Republican Yea
Wayne McMahen Republican Yea

Official roll call →

ADOPT (#1576)

Passed 36 Yea · 0 Nay · 3 Other
Party YeaNayPresentNot Voting
Unaffiliated 1000
Republican 25002
Democrat 10001
Total 36003
% of votes cast 92%0%0%8%
How each member voted (39)
Member Party Vote
Mr. President — Yea
Edward J. Price Democrat Yea
Gary Carter Democrat Yea
Gerald Boudreaux Democrat Yea
Jay Luneau Democrat Yea
Jimmy Harris Democrat Yea
Katrina R. Jackson-Andrews Democrat Yea
Larry Selders Democrat Not Voting
Regina Barrow Democrat Yea
Royce Duplessis Democrat Yea
Sam Jenkins Democrat Yea
Sidney Barthelemy II Democrat Yea
Adam Bass Republican Yea
Alan Seabaugh Republican Yea
Beth Mizell Republican Yea
Blake Miguez Republican Yea
Bob Hensgens Republican Yea
Brach Jerad Myers Republican Yea
Caleb Kleinpeter Republican Yea
Eddie J. Lambert Republican Yea
Franklin J. Foil Republican Yea
Glen Womack Republican Not Voting
Gregory A. Miller Republican Yea
Heather Cloud Republican Not Voting
Jeremy Stine Republican Yea
John C. "Jay" Morris Republican Yea
Jr., William "Bill" Wheat Republican Yea
Kirk Talbot Republican Yea
Mark Abraham Republican Yea
Michael "Big Mike" Fesi Republican Yea
Mike Reese Republican Yea
Patrick Connick Republican Yea
Patrick McMath Republican Yea
Rick Edmonds Republican Yea
Robert "Bob" Owen Republican Yea
Robert Allain Republican Yea
Stewart Jr. Cathey Republican Yea
Thomas A. Pressly Republican Yea
Valarie Hodges Republican Yea

Official roll call →

REJECT (#1184)

Passed 36 Yea · 0 Nay · 3 Other
Party YeaNayPresentNot Voting
Unaffiliated 1000
Republican 27000
Democrat 8003
Total 36003
% of votes cast 92%0%0%8%
How each member voted (39)
Member Party Vote
Mr. President — Yea
Edward J. Price Democrat Yea
Gary Carter Democrat Yea
Gerald Boudreaux Democrat Yea
Jay Luneau Democrat Yea
Jimmy Harris Democrat Yea
Katrina R. Jackson-Andrews Democrat Not Voting
Larry Selders Democrat Not Voting
Regina Barrow Democrat Yea
Royce Duplessis Democrat Not Voting
Sam Jenkins Democrat Yea
Sidney Barthelemy II Democrat Yea
Adam Bass Republican Yea
Alan Seabaugh Republican Yea
Beth Mizell Republican Yea
Blake Miguez Republican Yea
Bob Hensgens Republican Yea
Brach Jerad Myers Republican Yea
Caleb Kleinpeter Republican Yea
Eddie J. Lambert Republican Yea
Franklin J. Foil Republican Yea
Glen Womack Republican Yea
Gregory A. Miller Republican Yea
Heather Cloud Republican Yea
Jeremy Stine Republican Yea
John C. "Jay" Morris Republican Yea
Jr., William "Bill" Wheat Republican Yea
Kirk Talbot Republican Yea
Mark Abraham Republican Yea
Michael "Big Mike" Fesi Republican Yea
Mike Reese Republican Yea
Patrick Connick Republican Yea
Patrick McMath Republican Yea
Rick Edmonds Republican Yea
Robert "Bob" Owen Republican Yea
Robert Allain Republican Yea
Stewart Jr. Cathey Republican Yea
Thomas A. Pressly Republican Yea
Valarie Hodges Republican Yea

Official roll call →

FINAL PASSAGE (#1382)

Passed 96 Yea · 0 Nay · 9 Other
Party YeaNayPresentNot Voting
Unaffiliated 7000
Republican 62006
Democrat 27003
Total 96009
% of votes cast 91%0%0%9%
How each member voted (105)
Member Party Vote
Mr. Speaker — Yea
Amedee — Yea
Galle — Yea
Stagni — Yea
Johnson, T. — Yea
Landry, T. — Yea
St. Blanc — Yea
Adrian Fisher Democrat Yea
Aimee Adatto Freeman Democrat Yea
Alonzo L. Knox Democrat Yea
Barbara Carpenter Democrat Yea
C. Denise Marcelle Democrat Yea
Candace N. Newell Democrat Yea
Chasity Martinez Democrat Yea
Dana Henry Democrat Yea
Delisha Boyd Democrat Yea
Ed Murray Democrat Yea
Edmond Jordan Democrat Yea
Gerald Boudreaux Democrat Yea
III, Ed Larvadain Democrat Yea
Joy Walters Democrat Yea
Jr., Kyle M. Green Democrat Yea
Ken Brass Democrat Yea
Mandie Landry Democrat Not Voting
Marcus Anthony Bryant Democrat Yea
Pat Moore Democrat Yea
Rashid Armand Young Democrat Yea
Robby Carter Democrat Yea
Rodney Lyons Democrat Yea
Roy Daryl Adams Democrat Yea
Shaun Raphael Mena Democrat Not Voting
Sr., Wilford Carter Democrat Yea
Steven Jackson Democrat Yea
Sylvia Elaine Taylor Democrat Yea
Tammy T. Phelps Democrat Not Voting
Tehmi Jahi Chassion Democrat Yea
Vanessa Caston LaFleur Democrat Yea
Annie Spell Republican Yea
Barbara Reich Freiberg Republican Yea
Beth Anne Billings Republican Yea
Brett F. Geymann Republican Yea
Brian Leonard Glorioso Republican Yea
Bryan Fontenot Republican Yea
Chad Michael Boyer Republican Yea
Chance Keith Henry Republican Yea
Christopher Turner Republican Yea
Danny McCormick Republican Yea
Daryl Andrew Deshotel Republican Yea
Debbie Villio Republican Yea
Dixon Wallace McMakin Republican Not Voting
Dodie Horton Republican Yea
Emily Chenevert Republican Yea
Foy Bryan Gadberry Republican Yea
Francis C. Thompson Republican Not Voting
Gregory A. Miller Republican Yea
III, Roger William Wilder Republican Yea
III, Vincent E. Cox Republican Yea
IV, Gerald "Beau" Beaullieu Republican Yea
Jack McFarland Republican Yea
Jacob Braud Republican Yea
Jacob Jules Landry Republican Yea
Jason Brian DeWitt Republican Yea
Jeffrey "Jeff" Fons Wiley Republican Yea
Jeremy LaCombe Republican Yea
Jerome Zeringue Republican Not Voting
Jessica Domangue Republican Yea
John E. Wyble Republican Yea
Joseph A. Orgeron Republican Yea
Josh Carlson Republican Yea
Jr., Dennis Bamburg Republican Yea
Jr., John R. Illg Republican Yea
Jr., Michael Robert Bayham Republican Yea
Kathy Edmonston Republican Yea
Kellee Hennessy Dickerson Republican Yea
Kim Carver Republican Yea
Kimberly Landry Coates Republican Yea
Larry A. Bagley Republican Not Voting
Lauren Ventrella Republican Yea
Laurie Schlegel Republican Yea
Les Farnum Republican Not Voting
Mark Wright Republican Yea
Michael "Gabe" Firment Republican Yea
Michael Charles Echols Republican Yea
Michael Melerine Republican Yea
Mike Johnson Republican Yea
Neil Riser Republican Yea
Nicholas Muscarello Republican Yea
Paul Sawyer Republican Yea
Phillip Eric Tarver Republican Yea
Polly Thomas Republican Yea
R. Dewith Carrier Republican Yea
Raymond J. Crews Republican Yea
Reese "Skip" Broussard Republican Yea
Rhonda Gaye Butler Republican Yea
Robert "Bob" Owen Republican Yea
Rodney Schamerhorn Republican Yea
Ryan Bourriaque Republican Yea
Shane Mack Republican Yea
Sr., Peter F. Egan Republican Yea
Stephanie H. Berault Republican Yea
Stephanie Hilferty Republican Not Voting
Timothy P. Kerner Republican Yea
Tony Bacala Republican Yea
Troy Jude Hebert Republican Yea
Wayne McMahen Republican Yea

Official roll call →

FINAL PASSAGE (#359)

Passed 37 Yea · 0 Nay · 2 Other
Party YeaNayPresentNot Voting
Unaffiliated 1000
Republican 26001
Democrat 10001
Total 37002
% of votes cast 95%0%0%5%
How each member voted (39)
Member Party Vote
Mr. President — Yea
Edward J. Price Democrat Yea
Gary Carter Democrat Yea
Gerald Boudreaux Democrat Yea
Jay Luneau Democrat Yea
Jimmy Harris Democrat Yea
Katrina R. Jackson-Andrews Democrat Yea
Larry Selders Democrat Yea
Regina Barrow Democrat Not Voting
Royce Duplessis Democrat Yea
Sam Jenkins Democrat Yea
Sidney Barthelemy II Democrat Yea
Adam Bass Republican Yea
Alan Seabaugh Republican Yea
Beth Mizell Republican Yea
Blake Miguez Republican Yea
Bob Hensgens Republican Yea
Brach Jerad Myers Republican Yea
Caleb Kleinpeter Republican Yea
Eddie J. Lambert Republican Yea
Franklin J. Foil Republican Yea
Glen Womack Republican Yea
Gregory A. Miller Republican Yea
Heather Cloud Republican Yea
Jeremy Stine Republican Yea
John C. "Jay" Morris Republican Yea
Jr., William "Bill" Wheat Republican Yea
Kirk Talbot Republican Yea
Mark Abraham Republican Yea
Michael "Big Mike" Fesi Republican Yea
Mike Reese Republican Yea
Patrick Connick Republican Yea
Patrick McMath Republican Yea
Rick Edmonds Republican Yea
Robert "Bob" Owen Republican Yea
Robert Allain Republican Yea
Stewart Jr. Cathey Republican Yea
Thomas A. Pressly Republican Yea
Valarie Hodges Republican Not Voting

Official roll call →

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

Who sponsors SB 401?
SB 401 is sponsored by Tehmi Jahi Chassion (Democrat) and Kirk Talbot (Republican).
What is the current status of SB 401?
This bill has been enacted into law. Introduced February 27, 2026. Enacted.
Where can I track SB 401?
Track SB 401 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 401

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of SB 401

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →